Dermatitis atopic: FDA reporting patterns
49,301 FDA FAERS reports mention Dermatitis atopic. 3,898 reports have a serious outcome flag.
Medicines named as suspect
- Dupilumab: 44,934 reports
- Tralokinumab: 737 reports
- Upadacitinib: 665 reports
- Nemolizumab: 440 reports
- Tacrolimus: 276 reports
- Ruxolitinib: 221 reports
- Adalimumab: 171 reports
- Omalizumab: 157 reports
- Crisaborole: 134 reports
- Cyclosporine: 133 reports
- Prednisone: 121 reports
- Abrocitinib: 117 reports
FAERS reports describe events reported after a medicine was taken. They do not prove that the medicine caused an event, measure how often a side effect occurs, or estimate personal risk.
Source: FDA FAERS via openFDA. FAERS data through 2026-06-30. Sources, methods, and limitations.